The Trade Desk stock up 8 percent as firm sells 5 million shares
Shares of Ventura-based The Trade Desk jumped 8 percent to $35.00 as the company announced the launch of a 5 million share offering by current investors. At the company’s closing price on Feb. 21, the offering would have a gross value of around $165 million before a possible 10 percent overallotment, as disclosed in the Read More →
Genentech sues Amgen over biosimilar drug info
Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →
San Luis Obispo’s MindBody closes in on profitability
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
The Trade Desk reports strong income growth
The Trade Desk reported a 29 percent increase in net income in its fiscal year 2016 earnings statement Feb. 16 and filed a proposal with the Securities and Exchange Commission for a follow-on stock offering. The Ventura advertising platform company made $10.3 million in the fourth quarter of 2016 for a total of $20.5 million Read More →
AeroVironment releases pilot program details at expo
Unmanned aircraft systems company AeroVironment published details from its pilot program and debuted a new drone and support system at the World Ag Expo and National Farm Machinery Show Feb. 14 in Tulare, CA. Based in Monrovia, with operations in Simi Valley, the company partnered with farmers and universities to develop a drone that would Read More →
Amgen applies for FDA approval of Blincyto
Thousand Oaks-based Amgen submitted an application for Blincyto to the U.S. Food and Drug Administration, the company announced on Feb. 14. Amgen aims to gain approval for Blincyto to treat Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The drug was previously granted breakthrough therapy designation and accelerated approval in December 2014. “Acute Read More →
Westlake Village startups close in on Innovation Open prize
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
